Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, +17

The Lancet Oncology

Lymphoid NeoplasiaBispecific AntibodyMedicineImmunologyImmune Checkpoint Inhibitor +5

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Jeremy S. Abramson, Matthew Ku, Mark P. Hertzberg, +23

The Lancet

Hematological MalignancyOpen-label TrialLymphoid NeoplasiaMedicineImmunology +6

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, +21

Blood Advances

Hematological MalignancyRheumatologyLymphoid NeoplasiaHealth SciencesMedicine +13

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Ian W. Flinn, John G. Gribben, Martin J.S. Dyer, +17

Blood

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Sarit Assouline, Won Seog Kim, Laurie H. Sehn, +17

Blood

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, +17

Journal of Clinical Oncology

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Matthew J. Matasar, Chan Y. Cheah, Dok Hyun Yoon, +17

Blood

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, +18

Blood

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, +16

Blood

Lifestyle factors and long-term survival of gastric cancer patients: A large bidirectional cohort study from China

Lulu Zhao, Huang Huang, Yang Wang, +7

World Journal of Gastroenterology